Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) have been assigned a consensus rating of “Moderate Buy” from the twenty research firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $49.94.

Several research firms recently issued reports on APLS. Oppenheimer reduced their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Citigroup reduced their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. JPMorgan Chase & Co. lowered their price objective on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. The Goldman Sachs Group lowered Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a report on Tuesday, December 17th. Finally, William Blair started coverage on Apellis Pharmaceuticals in a report on Wednesday, October 16th. They set an “outperform” rating on the stock.

Apellis Pharmaceuticals Stock Performance

Shares of APLS stock opened at $32.68 on Friday. The firm has a market cap of $4.07 billion, a P/E ratio of -16.10 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The stock’s 50-day moving average is $30.75 and its two-hundred day moving average is $34.37.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. Apellis Pharmaceuticals’s revenue was up 78.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.17) EPS. Analysts predict that Apellis Pharmaceuticals will post -1.72 earnings per share for the current fiscal year.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after purchasing an additional 735,160 shares in the last quarter. Exome Asset Management LLC raised its stake in shares of Apellis Pharmaceuticals by 114.0% in the 3rd quarter. Exome Asset Management LLC now owns 100,367 shares of the company’s stock valued at $2,895,000 after buying an additional 53,467 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth about $390,000. Old West Investment Management LLC bought a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth about $2,953,000. Finally, Toronto Dominion Bank boosted its position in shares of Apellis Pharmaceuticals by 4.2% during the 3rd quarter. Toronto Dominion Bank now owns 25,622 shares of the company’s stock valued at $739,000 after acquiring an additional 1,022 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).